DnB Asset Management AS
- SEC CIK
- 0001456670
- Latest filing
- Aug 11, 2026
RARE holding history
Ultragenyx Pharmaceutical Inc. in every 13F filed by DnB Asset Management AS, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RARE overviewAll 13F holders of RAREFull Q2 2026 holdings
- Shares (Q2 2026)
- 6,920
- Value
- $231.1K
- % of portfolio
- <0.1%
- Quarters held
- 10
- Since Q2 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,920 | $231.1K | <0.1% | +6,920 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −17,479−100.0% | Sold out | Holders |
| Q3 2025 | 17,479 | $525.8K | <0.1% | +2,759+18.7% | Added | Holders |
| Q2 2025 | 14,720 | $535.2K | <0.1% | +452+3.2% | Added | Holders |
| Q1 2025 | 14,268 | $516.6K | <0.1% | +2,136+17.6% | Added | Holders |
| Q4 2024 | 12,132 | $510.4K | <0.1% | +1,889+18.4% | Added | Holders |
| Q3 2024 | 10,243 | $569.0K | <0.1% | −2,699−20.9% | Reduced | Holders |
| Q2 2024 | 12,942 | $531.9K | <0.1% | +2,921+29.1% | Added | Holders |
| Q1 2024 | 10,021 | $467.8K | <0.1% | +10,021 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −12,674−100.0% | Sold out | Holders |
| Q3 2023 | 12,674 | $451.8K | <0.1% | +848+7.2% | Added | Holders |
| Q2 2023 | 11,826 | $545.5K | <0.1% | +11,826 | New | Holders |